首页> 外文期刊>Revista Brasileira de Hematologia e Hemoterapia >Clinical course and prognostic factors of children with Burkitt's lymphoma in a developing country: the experience of a single centre in Brazil
【24h】

Clinical course and prognostic factors of children with Burkitt's lymphoma in a developing country: the experience of a single centre in Brazil

机译:发展中国家Burkitt淋巴瘤患儿的临床病程和预后因素:在巴西建立单一中心的经验

获取原文
           

摘要

OBJECTIVE: Burkitt's lymphoma is the most common subtype of non-Hodgkin lymphoma in children. The aim of this study was to characterize the clinical course and prognostic factors of children and adolescents with Burkitt's lymphoma treated in the Hematology Unit of Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG). METHODS: A retrospective cohort study was made of 50 consecutive cases of children and adolescents aged 16 years or less with Burkitt's lymphoma admitted between January 1981 and December 2007. Prognostic factors associated with death were evaluated using the Kaplan-Meier method and compared by the two-tailed log-rank test. RESULTS: The median age at diagnosis was 4.7 years. Most patients had abdominal tumors (66.7%) and advanced disease (68.9%) at diagnosis. Thirty-eight patients (84.4%) achieved complete clinical remission and 33 (73.3%) were alive at the first remission. Twelve children (26.7%) died. The median follow-up was 35 months with the probability of overall survival being 73% (89.2% and 35.7% for patients with uric acid < 7 mg/dL and 7.0 mg/dL, respectively - p-value < 0.001). Uric acid was the only significant prognostic factor at diagnosis. CONCLUSION: Our findings confirm the favorable prognosis of children with Burkitt's lymphoma even when treated with intermediate doses of methotrexate (500 mg/m2). Survival was significantly lower for individuals with concentrations of uric acid 7 mg/dL.
机译:目的:伯基特淋巴瘤是儿童非霍奇金淋巴瘤最常见的亚型。这项研究的目的是描述在米纳斯吉拉斯州立大学dasClínicas医院血液科治疗的Burkitt淋巴瘤的儿童和青少年的临床病程和预后因素。方法:对1981年1月至2007年12月期间收治的50例16岁以下Burkitt淋巴瘤儿童和青少年进行连续性队列研究。采用Kaplan-Meier方法评估与死亡相关的预后因素,并将两者进行比较尾对数秩检验。结果:诊断时的中位年龄为4.7岁。大多数患者在诊断时患有腹部肿瘤(66.7%)和晚期疾病(68.9%)。 38例患者(84.4%)完全临床缓解,初次缓解时33例(73.3%)仍然活着。十二名儿童(26.7%)死亡。中位随访时间为35个月,总生存率为73%(尿酸<7 mg / dL和> 7.0 mg / dL的患者分别为89.2%和35.7%-p值<0.001)。尿酸是诊断时唯一重要的预后因素。结论:我们的研究结果证实,即使接受中等剂量的甲氨蝶呤(500 mg / m2)治疗,伯吉特淋巴瘤患儿的预后也良好。尿酸浓度> 7 mg / dL的个体的存活率明显降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号